JP2010535215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535215A5 JP2010535215A5 JP2010519940A JP2010519940A JP2010535215A5 JP 2010535215 A5 JP2010535215 A5 JP 2010535215A5 JP 2010519940 A JP2010519940 A JP 2010519940A JP 2010519940 A JP2010519940 A JP 2010519940A JP 2010535215 A5 JP2010535215 A5 JP 2010535215A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- phenyl
- chloro
- disease
- thiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- -1 5- (2-chloro-5- (thiazol-2-yl) phenyl) pyridin-2-yl Chemical group 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- ACXBTXXLWDBYKS-UHFFFAOYSA-N 2-chloro-n-[5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]pyridin-2-yl]-6-fluorobenzamide Chemical compound FC1=CC=CC(Cl)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=N1 ACXBTXXLWDBYKS-UHFFFAOYSA-N 0.000 claims 1
- BYXHKOOCQBEYGY-UHFFFAOYSA-N 5-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]-n-[(2,6-difluorophenyl)methyl]pyridin-2-amine Chemical compound FC1=CC=CC(F)=C1CNC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)C=N1 BYXHKOOCQBEYGY-UHFFFAOYSA-N 0.000 claims 1
- NBDKYFMDIDEITR-UHFFFAOYSA-N 5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]-n-[(2,6-difluorophenyl)methyl]pyridin-2-amine Chemical compound FC1=CC=CC(F)=C1CNC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=N1 NBDKYFMDIDEITR-UHFFFAOYSA-N 0.000 claims 1
- ASOZGKVZZAHVIR-UHFFFAOYSA-N 5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]-n-[(2,6-difluorophenyl)methyl]pyridin-2-amine;hydrochloride Chemical compound Cl.FC1=CC=CC(F)=C1CNC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=N1 ASOZGKVZZAHVIR-UHFFFAOYSA-N 0.000 claims 1
- YODLCBZAHHBODR-UHFFFAOYSA-N 6-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]-n-[(2,6-difluorophenyl)methyl]pyridin-3-amine Chemical compound FC1=CC=CC(F)=C1CNC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)N=C1 YODLCBZAHHBODR-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010996 Corneal degeneration Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000024035 chronic otitis media Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- DCKUDEUBVRICMY-UHFFFAOYSA-N n-[(2,6-difluorophenyl)methyl]-6-[2-methyl-5-(1,2-oxazol-5-yl)phenyl]pyridin-3-amine Chemical compound CC1=CC=C(C=2ON=CC=2)C=C1C(N=C1)=CC=C1NCC1=C(F)C=CC=C1F DCKUDEUBVRICMY-UHFFFAOYSA-N 0.000 claims 1
- SBAPLPGPJAAFSI-UHFFFAOYSA-N n-[5-(2-chloro-5-pyridin-3-ylphenyl)pyridin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2C=NC=CC=2)Cl)C=N1 SBAPLPGPJAAFSI-UHFFFAOYSA-N 0.000 claims 1
- IZDQGPYRYVPZGU-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]pyridin-2-yl]-2-fluorobenzamide Chemical compound FC1=CC=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=N1 IZDQGPYRYVPZGU-UHFFFAOYSA-N 0.000 claims 1
- VTAHYLSZWGOEKT-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]pyridin-2-yl]-3-fluoropyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=N1 VTAHYLSZWGOEKT-UHFFFAOYSA-N 0.000 claims 1
- NATKAABNGICGME-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]pyridin-2-yl]-3-methyl-1h-pyrrole-2-carboxamide Chemical compound C1=CNC(C(=O)NC=2N=CC(=CC=2)C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)=C1C NATKAABNGICGME-UHFFFAOYSA-N 0.000 claims 1
- WNWVMBADEROJSP-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]pyridin-2-yl]-3-methylimidazole-4-carboxamide Chemical compound CN1C=NC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=N1 WNWVMBADEROJSP-UHFFFAOYSA-N 0.000 claims 1
- BVQBYMMVLQNSFP-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]pyridin-2-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound N1=CSC(C(=O)NC=2N=CC(=CC=2)C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)=C1C BVQBYMMVLQNSFP-UHFFFAOYSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96278907P | 2007-08-01 | 2007-08-01 | |
| US60/962,789 | 2007-08-01 | ||
| PCT/US2008/009306 WO2009017819A1 (en) | 2007-08-01 | 2008-07-31 | Pyridine compounds for inflammation and immune-related uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535215A JP2010535215A (ja) | 2010-11-18 |
| JP2010535215A5 true JP2010535215A5 (enExample) | 2011-09-15 |
| JP5431323B2 JP5431323B2 (ja) | 2014-03-05 |
Family
ID=40304689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519940A Expired - Fee Related JP5431323B2 (ja) | 2007-08-01 | 2008-07-31 | 炎症および免疫関連用途のためのピリジン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120064121A1 (enExample) |
| EP (1) | EP2182808A4 (enExample) |
| JP (1) | JP5431323B2 (enExample) |
| CA (1) | CA2695148A1 (enExample) |
| TW (1) | TW200911800A (enExample) |
| WO (1) | WO2009017819A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006081389A1 (en) | 2005-01-25 | 2006-08-03 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| WO2007087443A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| CA2640090A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| JP2009528273A (ja) | 2006-01-25 | 2009-08-06 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用の置換ビアリール化合物 |
| CA2645434A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceutical Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| EP2350064A1 (en) * | 2008-10-01 | 2011-08-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| AU2010321832B2 (en) | 2009-11-20 | 2014-08-14 | Amgen Inc. | Anti-Orai1 antigen binding proteins and uses thereof |
| AP3341A (en) * | 2010-10-30 | 2015-07-31 | Lupin Ltd | Oxazoline and isoxazoline derivatives as crac modulators |
| AU2013255441B2 (en) | 2012-05-02 | 2017-11-09 | Lupin Limited | Substituted pyrazole compounds as CRAC modulators |
| EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| US9725463B2 (en) | 2013-06-21 | 2017-08-08 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| EP3013810A1 (en) | 2013-06-24 | 2016-05-04 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| CN107847548B (zh) | 2015-05-18 | 2022-06-14 | 贝思以色列女会吏医学中心公司 | P物质、肥大细胞脱颗粒抑制剂和周围神经病 |
| JP2022508468A (ja) | 2018-09-14 | 2022-01-19 | ルヒゼン ファーマスティカルズ アクツィエンゲゼルシャフト | Ｃｒａｃ阻害剤およびコルチコステロイドを含む組成物ならびにそれらの使用方法 |
| US12486274B2 (en) | 2020-01-13 | 2025-12-02 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ545447A (en) * | 2003-07-23 | 2010-03-26 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
| WO2006083477A2 (en) * | 2005-01-07 | 2006-08-10 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| AU2007211276B2 (en) * | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
-
2008
- 2008-07-31 TW TW097128952A patent/TW200911800A/zh unknown
- 2008-07-31 CA CA2695148A patent/CA2695148A1/en not_active Abandoned
- 2008-07-31 WO PCT/US2008/009306 patent/WO2009017819A1/en not_active Ceased
- 2008-07-31 US US12/452,983 patent/US20120064121A1/en not_active Abandoned
- 2008-07-31 EP EP08794964A patent/EP2182808A4/en not_active Withdrawn
- 2008-07-31 JP JP2010519940A patent/JP5431323B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535218A5 (enExample) | ||
| JP2010535214A5 (enExample) | ||
| JP2010509342A5 (enExample) | ||
| JP2012504605A5 (enExample) | ||
| JP7258903B2 (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| JP2021176902A (ja) | ピロロ［１，２−ｂ］ピリダジン誘導体 | |
| US10273237B2 (en) | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | |
| WO2011042797A4 (en) | Pyrazole derivatives as modulators of calcium release -activated calcium channel | |
| CN105960405B (zh) | 谷氨酰胺酶抑制剂 | |
| JP6266639B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮαの調節に有用なアルキルアミド置換ピリミジン化合物 | |
| JP2018513215A5 (enExample) | ||
| JP2019501125A (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 | |
| CN113365982A (zh) | 酰胺二取代的吡啶或哒嗪化合物 | |
| JP2011529049A5 (enExample) | ||
| RU2014106020A (ru) | Ингибиторы втк | |
| JP2008513508A5 (enExample) | ||
| TW201619148A (zh) | 蛋白質激酶ｃ抑制劑及其使用方法 | |
| JP2018531886A5 (enExample) | ||
| TW202220963A (zh) | 化合物、組合物及方法 | |
| CA2824415A1 (en) | Benzamide derivatives as p2x7 receptor antagonists | |
| JP2016503010A5 (enExample) | ||
| CA2475708A1 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| JP2012504603A5 (enExample) | ||
| JP2013525356A5 (enExample) | ||
| RU2015116532A (ru) | Ингибиторы тирозинкиназы syk |